Development and evaluation of rapidly disintegrating tablets of Candesartan was written by Ansari, Mohammad Pravej;Iqbal, Majid Md.;Saraswat, Rohit. And the article was included in World Journal of Pharmaceutical Research in 2019.Quality Control of 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate This article mentions the following:
In the present work, Rapidly disintegrating tablets of Cadesartan cilexetil were designed with a view to enhance patient compliance by direct compression method. In the direct compression method, crospovidone, croscarmellose sodium, sodium starch glycolate as superdisintegrants were used along with Sweeteners and flavours were used to enhance the organoleptic properties of tablet. Tablets were prepared by direct compression technique. Directly compressible microcrystalline cellulose to enhance mouth feel. Prepared tablets were evaluated for thickness, uniformity of weight, hardness, friability, wetting time, in -vitro disintegration time, drug content and in vitro drug release. Short-term stability (40°C / 75% RH for 3 mo) and drug-excipient interaction study (IR spectroscopy) are also were studied. Disintegration time and drug release were taken as the basis to optimize the rapidly disintegrating tablet. All the formulations were evaluated for the influence of disintegrates and their concentrations on the characteristics of rapid disintegrating tablets mainly in terms of disintegration time and dissolution studies. The disintegration time of all formulation showed less than 37 s. Among the three superdisintegrants used, Crospovidon showed less disintegrating time followed by croscarmellose sodium and sodium starch gycolate. The relative efficiency of different superdisintegrants to improve the drug rate of tablets was in order, crospovidon > Croscarmellose sodium > sodium starch gycolate. In the experiment, the researchers used many compounds, for example, 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5Quality Control of 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate).
1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate (cas: 145040-37-5) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Quality Control of 1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem